Illumina, Inc. (NASDAQ: ILMN) today announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, 5-base sequencing, and proteomics technologies. The ability to ...

Spatial transcriptomics technologies opened the door for new kinds of biological measurements, allowing scientists to generate detailed maps of where genes are expressed in tissue. But most methods ...

Scope-X, an expanded version of the Seq-Scope spatial transcriptomics method. The technique overcomes diffusion limits and ...

Are you attending the ABRF Annual Meeting 2026? Here are the breakout sessions and workshops you won’t want to miss.

Breast cancer remains one of the most prevalent and life-threatening forms of cancer, impacting millions worldwide. This malignancy's heterogeneity and complexity have long posed significant ...

Spatial transcriptomics is a cutting-edge technique that characterizes gene expression within sections of tissue, such as ...

This is not incremental progress - it is a step-change that unlocks industrial-scale biology for drug discovery, toxicology, and AI-driven research. Our additional investment reflects our conviction ...

At AGBT, customers will present data demonstrating unparalleled scale and sensitivity in research spanning pulmonary fibrosis, prostate cancer, and 3D reconstructions of mouse brains Company expands ...

"Spatial transcriptomics opens entirely new pathways to gain crucial insight into the cellular function of organisms," said Steve Barnard, PhD, chief technology officer of Illumina. "Illumina spatial ...